Viatris Recalls
24 recalls on record in the United States
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 8 mg, 30-cou
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
View recall details →
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 4 mg, 30 -co
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 100 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 50 mcg, packaged in a) 90-
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 125 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 200 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 112 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 137 mcg, packaged in a) 90
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 88 mcg, packaged in a) 90-
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 25 mcg, packaged in a) 90-
Superpotent Drug and Subpotent Drug: potency failures obtained
View recall details →
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 8mg, 30-coun
Failed Impurities/Degradation Specifications
View recall details →
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 4mg, 30-coun
Failed Impurities/Degradation Specifications
View recall details →
Viatris Inc recalls Valacyclovir Tablets USP, 500 mg, 90 count bottles, Rx Only,
Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.
View recall details →
Viatris Inc recalls Levsin injection (hyoscyamine sulfate injection, USP), 0.5 m
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
View recall details →
Viatris Inc recalls Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only,
Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.
View recall details →
Viatris Inc recalls Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Do
Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
View recall details →
Viatris Inc recalls Ampicillin for Injection, USP, 2 grams/vial NDC 67457-352-02
Presence of Particulate Matter: A complaint was received for the presence of a single strand of hair in one vial.
View recall details →
Viatris Inc recalls Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-cou
Failed Dissolution Specifications: low out of specification results for dissolution.
View recall details →
Viatris Inc recalls alprazolam XR extended-release tablets, 3 mg, 60-count bottl
Failed Dissolution Specifications: low out-of-specification dissolution test results observed.
View recall details →
Viatris recalls Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-
Failed Dissolution Specifications
View recall details →
Viatris recalls Candesartan Cilexetil Tablets, USP 16 mg, 30 count bottles,
Failed Impurities/Degradation Specifications; out of specification for Related Compound
View recall details →